Send to

Choose Destination
Leuk Res. 2013 Jan;37(1):93-101. doi: 10.1016/j.leukres.2012.10.001. Epub 2012 Oct 23.

Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.

Author information

Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan.


Since BCR-ABL plays an essential role in the growth factor-independent proliferation of Philadelphia chromosome (Ph)+ leukemia cells, imatinib treatment of Ph+ leukemia cells inactivates signaling pathways of BCR-ABL, and subsequent addition of growth factors (GFs) could restore the signaling pathways without reactivating BCR-ABL. Here we demonstrated that non-lymphoid Ph+ leukemia cell lines responded to diverse GFs depending on their immunophenotype and gene expression of transcription factors and GF receptors, while lymphoid Ph+ leukemia cell lines restrictively responded to flit3 ligand and interleukin-7, suggesting that GF sensitivity of imatinib-treated Ph+ leukemia cells could be powerful for specifying their distinctive lineage.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center